Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: FMS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 14.28% | Avg. Invested days 39 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.61B USD | Price to earnings Ratio 24.9 | 1Y Target Price 26.8 |
Price to earnings Ratio 24.9 | 1Y Target Price 26.8 | ||
Volume (30-day avg) 344986 | Beta 0.91 | 52 Weeks Range 17.80 - 25.25 | Updated Date 04/1/2025 |
52 Weeks Range 17.80 - 25.25 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 2.58% | Basic EPS (TTM) 1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.78% | Operating Margin (TTM) 8.04% |
Management Effectiveness
Return on Assets (TTM) 2.85% | Return on Equity (TTM) 4.84% |
Valuation
Trailing PE 24.9 | Forward PE 12.42 | Enterprise Value 24986029879 | Price to Sales(TTM) 0.76 |
Enterprise Value 24986029879 | Price to Sales(TTM) 0.76 | ||
Enterprise Value to Revenue 1.19 | Enterprise Value to EBITDA 7.18 | Shares Outstanding 586827008 | Shares Floating 209464927 |
Shares Outstanding 586827008 | Shares Floating 209464927 | ||
Percent Insiders - | Percent Institutions 7.5 |
Analyst Ratings
Rating 3.17 | Target Price 23.45 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 3 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care. It has grown to become a leading provider of dialysis products and services worldwide.
Core Business Areas
- Dialysis Services: Provides dialysis treatment services to patients with chronic kidney failure through a network of dialysis centers.
- Dialysis Products: Manufactures and distributes dialysis machines, dialyzers, and other products used in dialysis treatment.
- Other Healthcare Services: Offers a range of other healthcare services, including acute care, vascular care, and pharmacy services.
Leadership and Structure
Fresenius Medical Care is led by a management board. The organizational structure includes regional segments and global functions.
Top Products and Market Share
Key Offerings
- Dialysis Machines: Produces a variety of dialysis machines, including the 2008T dialysis machine, used in dialysis centers and hospitals. The company claims to be one of the leading providers of dialysis machines worldwide. Key competitors are Baxter International and Nikkiso.
- Dialyzers: Manufactures dialyzers, which filter waste products from the blood during dialysis. Fresenius is a major dialyzer supplier globally. Competitors include Asahi Kasei Medical and Toray Medical.
- Dialysis Clinics: Operates a global network of dialysis clinics. Market share varies by region; Fresenius is a leading provider in many countries. Competitors include DaVita Healthcare Partners.
Market Dynamics
Industry Overview
The dialysis market is driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The market is characterized by consolidation and technological advancements.
Positioning
Fresenius Medical Care is a leading player in the dialysis market, with a strong global presence and a comprehensive portfolio of products and services. Its competitive advantages include its scale, integrated business model, and technological expertise.
Total Addressable Market (TAM)
The global dialysis market is projected to reach approximately $105 billion by 2030. Fresenius is well-positioned to capture a significant share of this market due to its leading position in dialysis services and products. Fresenius' global reach allows it to serve a large patient population. Its competitive advantages in distribution and operational efficiency and clinic locations enhance its ability to compete.
Upturn SWOT Analysis
Strengths
- Global market leader in dialysis products and services
- Extensive network of dialysis centers
- Integrated business model
- Strong brand recognition
- Large R&D budget
Weaknesses
- Exposure to regulatory risks and reimbursement pressures
- High debt levels
- Dependence on government healthcare programs
- Profitability impacted by inflationary environment
- Geographic revenue concentration
Opportunities
- Growing prevalence of chronic kidney disease
- Expansion into emerging markets
- Development of new dialysis technologies
- Acquisitions of smaller dialysis providers
- Increasing demand for home dialysis
Threats
- Competition from other dialysis providers
- Changes in reimbursement policies
- Technological disruptions
- Economic downturns
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- DVA
- BAX
- BMY
Competitive Landscape
Fresenius Medical Care's advantages include its global scale, integrated business model, and technological expertise. Disadvantages include its high debt levels and exposure to regulatory risks.
Major Acquisitions
NxStage Medical
- Year: 2019
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Fresenius's home dialysis business and strengthened its position in the market.
Growth Trajectory and Initiatives
Historical Growth: Fresenius Medical Care has historically grown through acquisitions and organic expansion of its dialysis services and product offerings.
Future Projections: Future growth is expected to be driven by the increasing prevalence of CKD/ESRD and expansion into new markets. Analyst estimates will need to be sourced.
Recent Initiatives: Recent strategic initiatives include expanding its home dialysis business and investing in new technologies.
Summary
Fresenius Medical Care is a leading provider of dialysis services and products with a strong global presence. Its integrated business model and scale provide competitive advantages. However, the company faces challenges related to regulatory risks, reimbursement pressures, and high debt levels. Future growth is expected to be driven by the increasing prevalence of CKD/ESRD.
Similar Companies
- DVA
- BAX
- BMY
- ABT
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 111513 | |
Full time employees 111513 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.